Chicken AMH / Anti-Mullerian Hormone ELISA Kit

Name: Chicken AMH / Anti-Mullerian Hormone ELISA Kit
SKU: DEIA-BJ2934
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma

Species Reactivity

Chicken

Detection Method

sELISA

Intended Use

This AMH ELISA kit is an ELISA designed for the quantitative determination of Chicken AMH. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Contents of Kit

No.	Components	Size	Storage Conditions
1	Coated 96-well Strip Plate	1	-20°C
2	Standard (Lyophilized)	2 vials	-20°C
3	Reference Standard & Sample Diluent	1 vial × 20 ml	2-8°C
4	Biotinylated Detection Antibody (100×)	1 vial × 120 μl	-20°C
5	Biotinylated Detection Antibody Diluent	1 vial × 14 ml	2-8°C
6	HRP Conjugate (100×)	1 vial × 120 μl	-20°C
7	HRP Conjugate Diluent	1 vial × 14 ml	2-8°C
8	Wash Buffer (25×)	1 vial × 30 ml	2-8°C
9	TMB Substrate	1 vial × 10 ml	2-8°C
10	Stop Solution	1 vial × 10 ml	2-8°C
11	Adhesive Plate Sealers	4

Storage

Store all kit components at 4°C. Store Coated 96-well Strip Plate, Standard, Biotinylated Detection Antibody and HRP Conjugate at -20°C if the kit will not be used within 1 month. The Substrate should never be frozen. Once individual reagents are opened it is recommended that the kit be used within 1 month. Unused Strip Plate wells should be stored at -20°C in a sealed bag containing desiccant in order to minimize exposure to moisture. Do not use the kit beyond its expiration date.

Precision

Intra-Assay: CV<5.02% Inter-Assay: CV<5.34%

Detection Range

0.31 - 20 ng/ml

Sensitivity

0.19 ng/ml

Standard Curve

Typical Data: The following standard curve is an example only and should not be used to calculate results for tested samples. A new standard curve must be generated for each set of samples tested.

Citations

Have you cited DEIA-BJ2934 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females

JOURNAL OF DERMATOLOGICAL TREATMENT

Authors: Bansal, Prekshi; Sardana, Kabir; Sharma, Lokesh; Garga, Umesh Chandra; Vats, Gauri

Abstract

Background: Adult female acne (AFA) occurs beyond 25 years of age and can present either as isolated acne or with hyperandrogenic signs. Methods: 120 females aged >= 25 years were evaluated for acne, hirsutism and androgenetic alopecia. Hormonal assessment included total testosterone (TT), sex hormone binding globulin (SHBG), free androgen index (FAI), Anti Mullerian Hormone (AMH), 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH) and prolactin. Polycystic ovary syndrome (PCOS) was diagnosed using Rotterdam's criteria. Results: The mean GAGS score was 15.57 +/- 4.04.71.66% females had acne with hyperandrogenic signs (hirsutism, 55.81%; hyperseborrhoea, 65.12%; irregular menses, 36.05%) and 18.33% had increased androgen levels. The group with hyperandrogenic signs had longer duration of disease, truncal acne, significant adolescent acne history, stress, inappropriate diet and PCOS compared to the isolated acne group. The mean androgen levels were higher in the former but the difference was statistically insignificant. Conclusions: Adult female acne can be associated with hyperandrogenic features though routine hormonal tests may not reveal an underlying abnormality except PCOS. End-organ hypersensitivity is the most plausible explanation and thus justifies the use of antiandrogens in its management.

Antimullerian Hormone and Oxidative Stress Biomarkers as Predictors of Successful Pregnancy in Polycystic Ovary Syndrome, Endometriosis and Tubal Infertility Factor

ACTA CHIMICA SLOVENICA

Authors: Fabjan, Teja; Vrtacnik-Bokal, Eda; Virant-Klun, Irma; Bedenk, Jure; Kumer, Kristina; Osredkar, Josko

Abstract

Oxidative stress in the follicular fluid (FF) is thought to be responsible for the abnormal development of oocytes. In our study patients with polycystic ovarian syndrome (PCOS), endometriosis, and tubal infertility factor (TIF), and healthy women with a male factor of infertility, were prospectively enrolled. From each patient, a sample of individual FF was collected from a dominant follicle. Concentration levels of TAS, 8-IP, 8-OHdG, and AMH were determined. In women with PCOS, we found significantly lower values of oxidative stress markers in the FF. 8-IP and TAS levels were lower in the FF of women with endometriosis. In women with TIF, we also found significantly lower values of all tested markers in the FF, except for 8-OHdG and AMH. We wanted to see whether the biomarker measured in the FF in an individual diagnosis could predict a successfully obtained embryo from this particular follicle. The FF 8-OHdG result in P COS patients stood out and proved to be a good predictive marker of matured and fertilized oocytes in these patients. Further research is needed to be able to apply the acquired knowledge in improving the outcome of IVF procedures.